Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
✨ AI Summary
🔊 جاري الاستماع
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. (Source: Bloomberg)